Proto Axiom
Finance · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
80 Mount St Se 303, North Sydney, New So...Website
www.protoaxiom.comRevenue
$11.1 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Proto Axiom
Proto Axiom is an Australian biotech investment incubator that provides early-stage funding and growth capital to support scientific breakthroughs from proof-of-concept to commercial success. The company works closely with founders to build biotechnology companies, leveraging world-class science and a hands-on approach. By combining patient capital with incubation support, Proto Axiom aims to bridge the gap between innovative research and market readiness. They invite researchers from Australian universities and health systems to participate in the country's largest pitch day in life sciences.Explore more
Proto Axiom Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Proto Axiom your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Proto Axiom has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Proto Axiom
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Proto Axiom is spiking on competitors!
Funding: Get notified immidiatlly once Proto Axiom has new funding data
Proto Axiom, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Proto Axiom launches new products
Earning: See what the market has to say on Proto Axiom recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Proto Axiom had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Proto Axiom
Compare insights from companies similar to Proto Axiom, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Proto Axiom is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Proto Axiom is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Proto Axiom.
Proto Axiom financials insights
Gather financial insights about Proto Axiom, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$15M
2024
Series B
$20M
Proto Axiom News & Media
Australia's Healthcare Innovators in Stroke and Paediatric Care Honoured at 2024 Challenger Summit
Life sciences investor Proto Axiom awards $250,000 in prizes at inaugural Summit SYDNEY, Oct. 23, 2024 /PRNewswire/ -- The 2024 Challenger Summit concluded with two visionary researchers recognised for their groundbreaking contributions to treatment of stroke and paediatric skin care. The Summit, a prestigious gathering of leading minds in medical research, was a platform for ideas and solutions that have the potential to reshape the future of medicine. Dr Daniel Beard from the University of New“Australia has long been a global leader in research, yet our biotech sector has not lived up ...
“Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential”Australian biotech incubator Proto Axiom announces $20M Series B first close
$20M unlocked for opportunities in Australian biotech innovation, valuing Proto Axiom at $90M SYDNEY, Aug. 13, 2024 /PRNewswire/ -- Proto Axiom, the Australian biomedical technology incubator has today announced a $20 million first close of its targeted $30 million Series B, to bolster Australia's biotechnology (biotech) sector through increased intellectual property (IP) retention. The Series B first close and $15M Series A announced in September 2022 gives Proto Axiom a cash value of $90 milliProto Axiom Launches The Challenger Summit: Australia's Premier Biotech Pitch-Event with over $250,000 in Grant Financing
SYDNEY, May 21, 2024 /PRNewswire/ -- Proto Axiom, Australia's first true biotech incubator, is thrilled to announce the launch of The Challenger Summit. The Challenger Summit will provide a unique platform for researchers to showcase their innovative biotech solutions, competing for over $250,000 in unencumbered grant financing. This inaugural pitch-event is designed to bring together the brightest minds from Australian universities, research institutes, and public health systems. The significan
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Proto Axiom
Sign Up For FreeTo access detailed company insights
Proto Axiom is an Australian biotech investment incubator that provides early-stage funding and growth capital to support scientific breakthroughs from proof-of-concept to commercial success. The company works closely with founders to build biotechnology companies, leveraging world-class science and a hands-on approach. By combining patient capital... Read More
